Innate Pharma S.A. (IPH.PA)
EUR 1.75
(-0.46%)
EUR 1.75
(-0.46%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 64.57 Million EUR | 4.77% |
| 2022 | 66.06 Million EUR | 10.22% |
| 2021 | 59.93 Million EUR | -20.49% |
| 2020 | 75.38 Million EUR | 48.19% |
| 2019 | 50.86 Million EUR | -31.95% |
| 2018 | 74.74 Million EUR | 2.94% |
| 2017 | 72.61 Million EUR | 49.44% |
| 2016 | 48.58 Million EUR | 69.42% |
| 2015 | 28.67 Million EUR | 227.35% |
| 2014 | 8.76 Million EUR | 14.33% |
| 2013 | 7.66 Million EUR | 11.33% |
| 2012 | 6.88 Million EUR | -61.05% |
| 2011 | 17.67 Million EUR | 21.18% |
| 2010 | 14.58 Million EUR | -26.73% |
| 2009 | 19.9 Million EUR | -6.87% |
| 2008 | 21.37 Million EUR | 3.67% |
| 2007 | 20.61 Million EUR | 84.36% |
| 2006 | 11.18 Million EUR | 65.15% |
| 2005 | 6.77 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 4.79 Million EUR | 18.91% |
| 2024 Q2 | 4.79 Million EUR | 0.0% |
| 2023 Q4 | 4.02 Million EUR | 0.0% |
| 2023 Q3 | 4.02 Million EUR | -89.1% |
| 2023 Q1 | 3.83 Million EUR | -88.96% |
| 2023 FY | 69.21 Million EUR | 4.77% |
| 2023 Q2 | 36.95 Million EUR | 863.8% |
| 2022 FY | 66.06 Million EUR | 10.22% |
| 2022 Q1 | 7.13 Million EUR | -77.23% |
| 2022 Q2 | 35.05 Million EUR | 391.61% |
| 2022 Q3 | 24.99 Million EUR | -28.71% |
| 2022 Q4 | 34.73 Million EUR | 38.98% |
| 2021 Q1 | 4.79 Million EUR | -87.33% |
| 2021 FY | 59.93 Million EUR | -20.49% |
| 2021 Q3 | 6.8 Million EUR | -79.82% |
| 2021 Q2 | 33.7 Million EUR | 603.31% |
| 2021 Q4 | 31.31 Million EUR | 360.31% |
| 2020 FY | 75.38 Million EUR | 48.19% |
| 2020 Q1 | 7.87 Million EUR | -83.97% |
| 2020 Q4 | 37.84 Million EUR | 25.52% |
| 2020 Q3 | 30.14 Million EUR | -23.23% |
| 2020 Q2 | 39.27 Million EUR | 398.67% |
| 2019 Q2 | 39.05 Million EUR | 667.32% |
| 2019 Q3 | 9.48 Million EUR | -75.72% |
| 2019 Q4 | 49.13 Million EUR | 418.16% |
| 2019 FY | 50.86 Million EUR | -31.95% |
| 2019 Q1 | 5.08 Million EUR | -37.82% |
| 2018 Q1 | 3.39 Million EUR | -48.56% |
| 2018 FY | 74.74 Million EUR | 2.94% |
| 2018 Q4 | 8.18 Million EUR | 0.0% |
| 2018 Q3 | 8.18 Million EUR | 141.1% |
| 2018 Q2 | 3.39 Million EUR | 0.0% |
| 2017 Q1 | 6.49 Million EUR | 443.14% |
| 2017 FY | 72.61 Million EUR | 49.44% |
| 2017 Q4 | 6.59 Million EUR | 0.0% |
| 2017 Q3 | 6.59 Million EUR | 1.59% |
| 2017 Q2 | 6.49 Million EUR | 0.0% |
| 2016 Q2 | 1.75 Million EUR | 0.0% |
| 2016 FY | 48.58 Million EUR | 69.42% |
| 2016 Q4 | 1.19 Million EUR | 0.0% |
| 2016 Q3 | 1.19 Million EUR | -32.01% |
| 2016 Q1 | 1.75 Million EUR | 18.05% |
| 2015 Q1 | 80 Thousand EUR | -10.11% |
| 2015 FY | 28.67 Million EUR | 227.35% |
| 2015 Q2 | 80 Thousand EUR | 0.0% |
| 2015 Q4 | 1.49 Million EUR | 0.0% |
| 2015 Q3 | 1.49 Million EUR | 1762.5% |
| 2014 Q3 | 89 Thousand EUR | -96.34% |
| 2014 Q1 | 2.43 Million EUR | -4.59% |
| 2014 Q2 | 2.43 Million EUR | 0.0% |
| 2014 Q4 | 89 Thousand EUR | 0.0% |
| 2014 FY | 8.76 Million EUR | 14.33% |
| 2013 Q3 | 2.55 Million EUR | 27.85% |
| 2013 Q1 | 1.99 Million EUR | -10.56% |
| 2013 FY | 7.66 Million EUR | 11.33% |
| 2013 Q4 | 2.55 Million EUR | 0.0% |
| 2013 Q2 | 1.99 Million EUR | 0.0% |
| 2012 Q4 | 2.23 Million EUR | 0.0% |
| 2012 FY | 6.88 Million EUR | -61.05% |
| 2012 Q3 | 2.23 Million EUR | 0.0% |
| 2011 FY | 17.67 Million EUR | 21.18% |
| 2010 FY | 14.58 Million EUR | -26.73% |
| 2009 FY | 19.9 Million EUR | -6.87% |
| 2008 FY | 21.37 Million EUR | 3.67% |
| 2007 FY | 20.61 Million EUR | 84.36% |
| 2006 FY | 11.18 Million EUR | 65.15% |
| 2005 FY | 6.77 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.17 Million EUR | -1445.847% |
| ABIVAX Société Anonyme | 127.37 Million EUR | 49.308% |
| Adocia SA | 15.62 Million EUR | -313.142% |
| Aelis Farma SA | 18.81 Million EUR | -243.111% |
| Biophytis S.A. | 14.33 Million EUR | -350.499% |
| Advicenne S.A. | 8.21 Million EUR | -686.001% |
| genOway Société anonyme | 16.73 Million EUR | -285.762% |
| IntegraGen SA | 5.35 Million EUR | -1106.35% |
| Medesis Pharma S.A. | 1.56 Million EUR | -4027.007% |
| Neovacs S.A. | 10.34 Million EUR | -524.254% |
| NFL Biosciences SA | 4.37 Million EUR | -1376.104% |
| Plant Advanced Technologies SA | 2.76 Million EUR | -2235.389% |
| Quantum Genomics Société Anonyme | 1.71 Million EUR | -3658.517% |
| Sensorion SA | 27.05 Million EUR | -138.674% |
| Theranexus Société Anonyme | 3 Million EUR | -2048.761% |
| TME Pharma N.V. | 5.49 Million EUR | -1074.641% |
| Valbiotis SA | 9.86 Million EUR | -554.271% |
| TheraVet SA | 1.64 Million EUR | -3826.868% |
| Valerio Therapeutics Société anonyme | 20.32 Million EUR | -217.766% |
| DBV Technologies S.A. | 89.4 Million EUR | 27.779% |
| Genfit S.A. | 54.8 Million EUR | -17.82% |
| GeNeuro SA | 14.35 Million EUR | -349.736% |
| Inventiva S.A. | 120.18 Million EUR | 46.275% |
| MaaT Pharma SA | 21.59 Million EUR | -198.963% |
| MedinCell S.A. | 32.92 Million EUR | -96.13% |
| Nanobiotix S.A. | 58.92 Million EUR | -9.576% |
| OSE Immunotherapeutics SA | 23.58 Million EUR | -173.729% |
| Poxel S.A. | 28.76 Million EUR | -124.474% |
| GenSight Biologics S.A. | 32.66 Million EUR | -97.704% |
| Transgene SA | 31.23 Million EUR | -106.75% |
| Valneva SE | 134.92 Million EUR | 52.143% |